New and Generic Drug Approvals
October 23, 2014
| Drug Name | Active Ingredient | Dosage Form/Route | Sponsor | Submission Type |
|---|---|---|---|---|
| Abacavir and Lamivudine | abacavir;lamivudine | Tablet, For Suspension;Oral | Mylan Labs Ltd | Tentative Approval |
| Abacavir and Lamivudine | abacavir;lamivudine | Tablet;Oral | Mylan Labs Ltd | Tentative Approval |
| Adrenaclick | epinephrine | Injectable;Intramuscular, Subcutaneous | Amedra Pharms | Manufacturing Change or Addition |
| Astelin | azelastine hydrochloride | Spray, Metered;Nasal | Meda Pharms | Labeling Revision |
| Cancidas | caspofungin acetate | Injectable;Iv (Infusion) | Merck | Labeling Revision |
| Dilatrate-Sr | isosorbide dinitrate | Capsule, Extended Release;Oral | Auxilium Pharms Llc | Labeling Revision |
| Finacea | azelaic acid | Gel;Topical | Bayer Hlthcare | Manufacturing Change or Addition |
| Luvox | fluvoxamine maleate | Tablet;Oral | Ani Pharms | Manufacturing Change or Addition |
| Minocin | minocycline hydrochloride | Injectable;Injection | Rempex Pharms Inc | Labeling Revision |
| Phenylephrine Hydrochloride | phenylephrine hydrochloride | Solution;Iv (Infusion) | West Ward Pharm Corp | Manufacturing Change or Addition |
| Sodium Iodide I 131 | sodium iodide i-131 | Capsule;Oral | Mallinckrodt | Manufacturing Change or Addition |
| Somatuline Depot | lanreotide acetate | Injectable;Subcutaneous | Ipsen Pharma | Manufacturing Change or Addition |
| Tudorza Pressair | aclidinium bromide | Powder, Metered;Inhalation | Forest Labs Inc | Manufacturing Change or Addition |
| Twinject 0.15 | epinephrine | Injectable;Intramuscular, Subcutaneous | Amedra Pharms | Manufacturing Change or Addition |
| Twinject 0.3 | epinephrine | Injectable;Intramuscular, Subcutaneous | Amedra Pharms | Manufacturing Change or Addition |
| Uloric | febuxostat | Tablet;Oral | Takeda Pharms Usa | Manufacturing Change or Addition |
| Zetonna | ciclesonide | Aerosol, Metered;Nasal | Takeda Gmbh | Efficacy Supplement with Clinical Data to Support |
No comments:
Post a Comment